Hillstream Signs an Exclusive Agreement with Applied Biomedical Science Institute to License Technology for HER2 and HER3 Antibody Drug Conjugates
Shots:
- Hillstream & ABSI collaborated on licensing of technology for human Abs targeting novel HER2 and HER3 conformational epitopes. The purpose of the agreement is to develop proprietary multi-format biologics, incl. bi-specific Abs and ADCs to combat drug-resistant cancers i.e., HER2+ metastatic breast cancer, gastric cancer, lung cancer, and ovarian cancer
- Hillstream to get the rights to develop HER2 and HER3 Abs incl. multi-specific, ADC, and Quatramer-based therapeutics utilizing portions of these Abs
- HER2/HER3 binding ADC is designed to have a high drug-to-antibody ratio intended to enhance the bystander-killing effect and be effective against some epithelial tumors
Ref: Globenewswire | Image: Applied Biomedical Science
Related News:- Mersana Therapeutics Reports US FDA’s Partial Clinical Hold on New Patient Enrollment of UpRi for Platinum-Sensitive Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
